Equillium, Inc(NASDAQ:EQ) 
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune ...
Website: http://www.equilliumbio.com
Founded: 2017
Full Time Employees: 26
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 0.46
H 0.53
L 0.44
C 0.47
V 171,275
10EMA 0.47
20EMA 0.47
60EMA 0.47
120EMA 0.47
250EMA 0.47